1,000 Patients Treated with OssDsign Catalyst in the U.S.

OssDsign Catalyst Bone Substitute

OssDsign announced that 1,000 patients have been treated in the U.S. with OssDsign Catalyst nanosynthetic bone graft.

The product has been very well received in the U.S. market since its launch in 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us